JP2023505221A5 - - Google Patents

Info

Publication number
JP2023505221A5
JP2023505221A5 JP2022533441A JP2022533441A JP2023505221A5 JP 2023505221 A5 JP2023505221 A5 JP 2023505221A5 JP 2022533441 A JP2022533441 A JP 2022533441A JP 2022533441 A JP2022533441 A JP 2022533441A JP 2023505221 A5 JP2023505221 A5 JP 2023505221A5
Authority
JP
Japan
Prior art keywords
compound according
compound
alkyl
pharmaceutical composition
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022533441A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505221A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063137 external-priority patent/WO2021113528A1/en
Publication of JP2023505221A publication Critical patent/JP2023505221A/ja
Publication of JP2023505221A5 publication Critical patent/JP2023505221A5/ja
Pending legal-status Critical Current

Links

JP2022533441A 2019-12-04 2020-12-03 プログラム死リガンド１および／またはプログラム死リガンド２の調節物質 Pending JP2023505221A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943728P 2019-12-04 2019-12-04
US62/943,728 2019-12-04
PCT/US2020/063137 WO2021113528A1 (en) 2019-12-04 2020-12-03 Modulators of programmed death-ligand-1 and/or programmed death-ligand-2

Publications (2)

Publication Number Publication Date
JP2023505221A JP2023505221A (ja) 2023-02-08
JP2023505221A5 true JP2023505221A5 (enExample) 2023-11-29

Family

ID=76222302

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022533441A Pending JP2023505221A (ja) 2019-12-04 2020-12-03 プログラム死リガンド１および／またはプログラム死リガンド２の調節物質

Country Status (6)

Country Link
US (1) US12098216B2 (enExample)
EP (1) EP4069270A4 (enExample)
JP (1) JP2023505221A (enExample)
AU (1) AU2020396100A1 (enExample)
CA (1) CA3159698A1 (enExample)
WO (1) WO2021113528A1 (enExample)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1144373B1 (en) 1999-01-13 2005-10-19 Genentech, Inc. Serine protease inhibitors
GB0514071D0 (en) * 2005-07-07 2005-08-17 Zealand Pharma As N- or C- terminally modified small peptides
EP3092244B1 (en) 2014-01-10 2019-08-14 Cornell University Dipeptides as inhibitors of human immunoproteasomes
WO2019084455A1 (en) 2017-10-26 2019-05-02 Southern Research Institute DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS

Similar Documents

Publication Publication Date Title
JP2021522197A5 (enExample)
WO2023183585A1 (en) Kras inhibitors
EP2879677B1 (en) Substituted pyrazolone compounds and methods of use
JP6382831B2 (ja) アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト
CN102497862B (zh) 使用ck2调节剂的组合治疗
HRP20100563T1 (hr) Derivati dihidropirazolopirimidinona
JP2009514881A5 (enExample)
JP2016502544A5 (enExample)
JP2017521420A5 (enExample)
JP2006508981A5 (enExample)
JP2010533206A5 (enExample)
JP2008528469A5 (enExample)
KR20170090408A (ko) 벤조-헤테로시클릭 화합물 및 이의 적용
HRP20100561T1 (hr) Inhibitori interakcije između mdm2 i p53
JP2023526283A5 (enExample)
JP2011515397A5 (enExample)
JP2019501195A5 (ja) 腫瘍を処置するための抗ｅｇｆｒ組み合わせ
RU2016118753A (ru) Производные пиридилкетона, способ их получения и их фармацевтическое применение
WO2024217502A1 (en) Methionine adenosyltransferase 2a (mat2a) inhibitor combinations and uses thereof
JP2022537358A5 (enExample)
JP2012518598A5 (enExample)
WO2011028135A1 (en) Kinase inhibitors, prodrug forms thereof and their use in therapy
JP2023524912A5 (enExample)
JP2019533652A5 (enExample)
AU2002259309B2 (en) Antineoplastic combinations